{"id":51856,"date":"2022-12-12T15:02:25","date_gmt":"2022-12-12T14:02:25","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/yaral-pharma-launches-in-the-us\/"},"modified":"2022-12-12T15:02:25","modified_gmt":"2022-12-12T14:02:25","slug":"yaral-pharma-launches-in-the-us","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/yaral-pharma-launches-in-the-us\/","title":{"rendered":"Yaral Pharma Launches in the US"},"content":{"rendered":"
\n

\nUS Subsidiary of IBSA to Commercialize Generic Portfolio<\/i>\n<\/p>\n

PARSIPPANY, N.J.–(BUSINESS WIRE)–Yaral Pharma Inc.<\/a>, the US generics subsidiary of IBSA, a long-standing, multinational pharmaceutical company headquartered in Lugano, Switzerland, launched today with the mission of providing access to high quality, affordable, authorized generics (AG) and complex generic medicines to enhance healthcare outcomes.\n<\/p>\n

<\/a><\/p>\n

\nLed by a team of industry veterans, Yaral Pharma will begin commercializing the first product from IBSA\u2019s corporate pipeline of authorized generics in January 2023. Yaral Pharma\u2019s current portfolio includes products across a range of therapeutic areas, including pain and endocrinology. It plans to rapidly expand its product line and therapeutic areas of focus through outside opportunities and external partnerships.\n<\/p>\n

\nIBSA is particularly known for its manufacturing expertise and decades-long track record of product quality and supply continuity. The Company continues to build a wide-ranging portfolio of products across brands and generics in ten core therapeutic areas including pain and inflammation and endocrinology and manufactures novel delivery systems including soft gel capsules and patch technology. IBSA is also recognized as one of the largest players worldwide in the area of reproductive medicine and one of the world\u2019s leaders in hyaluronic acid-based products.\n<\/p>\n

\n\u201cOur parent company IBSA is recognized as a world leader in the development of innovative technologies and products that improve the health and wellness of people,\u201d said Stephen Beckman, CEO, Yaral Pharma. \u201cWe look forward to drawing on these strengths and providing our customers with high-quality products, continuity of supply, and exceptional levels of service.\u201d\n<\/p>\n

\nFor the latest updates on Yaral Pharma, please visit www.yaral-pharma.com<\/a> or connect with us on LinkedIn<\/a>.\n<\/p>\n

\nAbout Authorized Generics
\n
<\/b>According to the U.S. Food and Drug Administration, the term \u201cauthorized generic\u201d drug is most commonly used to describe an approved brand name drug that is marketed without the brand name on its label. Other than the fact that it does not have the brand name on its label, it is the exact same drug product as the branded product. The product the patient receives is identical to the branded product, contains the same active and inactive ingredients, and is manufactured using the same process at a considerable cost savings.\n<\/p>\n

\nAbout Yaral Pharma
\n
<\/b>Yaral Pharma Inc. (Parsippany, NJ) is the US generics subsidiary of IBSA, a global pharmaceutical company headquartered in Switzerland. By focusing on people and innovating the ways they\u2019re cared for, Yaral Pharma is proud to offer the same values and expertise of its parent company to the US market. Dedicated to ensuring access to affordable authorized generics (AGs) and complex generic medicines that enhance healthcare outcomes, Yaral Pharma offers its customers high-quality products across a range of therapeutic areas, continuity of supply, and a commitment to exceptional customer service. For more information, visit www.yaral-pharma.com<\/a> or contact info@yaral-pharma.com<\/a> or 866-218-9009.\n<\/p>\n

\nAbout IBSA
\n
<\/b>IBSA (Institut Biochimique SA<\/i>) is a Swiss multinational pharmaceutical Company, founded in 1945 in Lugano. Today, its products are present in over 90 Countries on 5 continents, through the Company\u2019s 17 subsidiaries located in Europe, China, and the United States. The company has a consolidated turnover of 800 million CHF, and employs over 2,000 people between headquarters, subsidiaries and production sites. IBSA holds 90 families of approved patents, plus others under development, as well as a vast portfolio of products, covering 10 therapeutic areas: reproductive medicine, endocrinology, pain and inflammation, osteoarticular, aesthetic medicine, dermatology, uro-gynaecology, cardiometabolic, respiratory, consumer health. It is also one of the largest operators worldwide in the area of reproductive medicine, and one of the world\u2019s leaders in hyaluronic acid-based products. IBSA has based its philosophy on four pillars: Person, Innovation, Quality and Responsibility.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nDaina Basile
\n
Kovak-Likly Communications
\n
203-762-8833, dbasile@klcpr.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

US Subsidiary of IBSA to Commercialize Generic Portfolio PARSIPPANY, N.J.–(BUSINESS WIRE)–Yaral Pharma Inc., the US generics subsidiary of IBSA, a long-standing, multinational pharmaceutical company headquartered in Lugano, Switzerland, launched today with the mission of providing access to high quality, affordable, authorized generics (AG) and complex generic medicines to enhance healthcare outcomes. Led by a team … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-51856","6":"format-standard","7":"category-industry"},"yoast_head":"\nYaral Pharma Launches in the US - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/yaral-pharma-launches-in-the-us\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Yaral Pharma Launches in the US - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"US Subsidiary of IBSA to Commercialize Generic Portfolio PARSIPPANY, N.J.–(BUSINESS WIRE)–Yaral Pharma Inc., the US generics subsidiary of IBSA, a long-standing, multinational pharmaceutical company headquartered in Lugano, Switzerland, launched today with the mission of providing access to high quality, affordable, authorized generics (AG) and complex generic medicines to enhance healthcare outcomes. Led by a team ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/yaral-pharma-launches-in-the-us\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-12-12T14:02:25+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20221205005017\/en\/1651131\/21\/Yaral_FullColor_RBG.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/yaral-pharma-launches-in-the-us\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/yaral-pharma-launches-in-the-us\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Yaral Pharma Launches in the US\",\"datePublished\":\"2022-12-12T14:02:25+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/yaral-pharma-launches-in-the-us\\\/\"},\"wordCount\":623,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/yaral-pharma-launches-in-the-us\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221205005017\\\/en\\\/1651131\\\/21\\\/Yaral_FullColor_RBG.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/yaral-pharma-launches-in-the-us\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/yaral-pharma-launches-in-the-us\\\/\",\"name\":\"Yaral Pharma Launches in the US - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/yaral-pharma-launches-in-the-us\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/yaral-pharma-launches-in-the-us\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221205005017\\\/en\\\/1651131\\\/21\\\/Yaral_FullColor_RBG.jpg\",\"datePublished\":\"2022-12-12T14:02:25+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/yaral-pharma-launches-in-the-us\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/yaral-pharma-launches-in-the-us\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/yaral-pharma-launches-in-the-us\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221205005017\\\/en\\\/1651131\\\/21\\\/Yaral_FullColor_RBG.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221205005017\\\/en\\\/1651131\\\/21\\\/Yaral_FullColor_RBG.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/yaral-pharma-launches-in-the-us\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Yaral Pharma Launches in the US\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Yaral Pharma Launches in the US - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/yaral-pharma-launches-in-the-us\/","og_locale":"en_US","og_type":"article","og_title":"Yaral Pharma Launches in the US - Pharma Trend","og_description":"US Subsidiary of IBSA to Commercialize Generic Portfolio PARSIPPANY, N.J.–(BUSINESS WIRE)–Yaral Pharma Inc., the US generics subsidiary of IBSA, a long-standing, multinational pharmaceutical company headquartered in Lugano, Switzerland, launched today with the mission of providing access to high quality, affordable, authorized generics (AG) and complex generic medicines to enhance healthcare outcomes. Led by a team ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/yaral-pharma-launches-in-the-us\/","og_site_name":"Pharma Trend","article_published_time":"2022-12-12T14:02:25+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20221205005017\/en\/1651131\/21\/Yaral_FullColor_RBG.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/yaral-pharma-launches-in-the-us\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/yaral-pharma-launches-in-the-us\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Yaral Pharma Launches in the US","datePublished":"2022-12-12T14:02:25+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/yaral-pharma-launches-in-the-us\/"},"wordCount":623,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/yaral-pharma-launches-in-the-us\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221205005017\/en\/1651131\/21\/Yaral_FullColor_RBG.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/yaral-pharma-launches-in-the-us\/","url":"https:\/\/pharma-trend.com\/en\/yaral-pharma-launches-in-the-us\/","name":"Yaral Pharma Launches in the US - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/yaral-pharma-launches-in-the-us\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/yaral-pharma-launches-in-the-us\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221205005017\/en\/1651131\/21\/Yaral_FullColor_RBG.jpg","datePublished":"2022-12-12T14:02:25+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/yaral-pharma-launches-in-the-us\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/yaral-pharma-launches-in-the-us\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/yaral-pharma-launches-in-the-us\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20221205005017\/en\/1651131\/21\/Yaral_FullColor_RBG.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20221205005017\/en\/1651131\/21\/Yaral_FullColor_RBG.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/yaral-pharma-launches-in-the-us\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Yaral Pharma Launches in the US"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/51856","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=51856"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/51856\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=51856"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=51856"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=51856"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}